Testing iptacopan for children with IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and 18 years old
- Have IgA nephropathy confirmed by a kidney biopsy
- Have protein in your urine despite taking standard blood pressure medications for at least 4 months
- Weigh at least 35 kg (for one part of the study)
- Must have certain vaccines (against meningitis and pneumonia) before starting treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
This study collects real-world information from people with IgA nephropathy who are being treated with one of two medicines, iptacopan or atrasentan. The goal is to understand how these treatments work in everyday practice, which may help improve care for others with the condition.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This study looks at how well iptacopan works for people with C3G, a kidney disease. It aims to see if the treatment is safe and effective, and includes people who have already taken iptacopan.
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Hear when a new Primary Immunoglobulin A Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.